Karl-Johan Leuchowius
Karl-Johan Leuchowius did his PhD in Ulf Landegren’s lab in Uppsala, Sweden, developing the in situ proximity ligation assay (PLA). In 2010, he joined the high throughput screening facility at the Walter+Eliza Hall Institute in Melbourne, Australia, where he worked on assay development and screening of small molecules and siRNA using high content screening, and established the institute’s platform for arrayed CRISPR screening. In 2018, he joined AstraZeneca in Gothenburg, Sweden, where he worked with assay development and profiling of small molecules, then later therapeutic oligonucleotides. Since 2023, he has led the Oligo Assay Development team, with the remit of providing assays to the internal therapeutic oligonucleotide projects.